12 June 2020
EMA/323441/2020
EMEA/H/C/001042

Public statement

Fertavid

Withdrawal of the marketing authorisation in the European Union

On 23 January 2020, the European Commission withdrew the marketing authorisation for Fertavid (follitropin beta) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Fertavid was granted marketing authorisation in the EU on 19 March 2009 for treatment of infertility. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Fertavid is an identical product to Puregon, which is authorised in the EU to treat infertility. The marketing authorisation holder will maintain the marketing authorisation for Puregon.

The European Public Assessment Report (EPAR) for Fertavid will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union